DTIL Precision BioSciences
- 12.0900
- +0.4700+4.04%
Precision BioSciences News
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Adicet Bio (ACET)
Maintaining Hold on Precision BioSciences Pending Clinical Data and Strategic Reassessments
Buy Rating Affirmed for Precision BioSciences on Advancing Gene Editing Pipeline and Strong Financials
Quarterly Results Takes Precision BioSciences Higher
Precision BioSciences Reports Profit From Cont. Ops. In Q1
Precision BioSciences | 10-Q: Quarterly report
Precision BioSciences Q1 EPS $1.70 Beats $(1.91) Estimate, Sales $17.58M Beat $6.02M Estimate
Precision BioSciences (NASDAQ:DTIL) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $(1.91) by 189.01 percent. This is a 124.64 percent increase over losses
Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q1 Revenue $17.6M, Vs. Street Est of $6.02M
07:02 AM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q1 Revenue $17.6M, vs. Street Est of $6.02M
Precision Biosciences 1Q Rev $17.6M >DTIL
Precision Biosciences 1Q Rev $17.6M >DTIL
Press Release: Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update - Wholly owned programs on track for CTA and/or IND submissions - PBGENE-HBV for Hepatitis B virus in 2
Stocks Poised for Lower Open -- Barrons.com
By Janet H. Cho Stocks are poised to open lower in New York on Monday as investors await a key inflation reading later in the week and ahead of earnings reports from major retailers. At 6:22 p.m. ET
Precision BioSciences Announces Common Stock Purchase By Members Of Management, Including CEO, For $300,000 In Private Placement
Precision BioSciences Announces Common Stock Purchase By Members Of Management, Including CEO, For $300,000 In Private Placement
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (the "Company"), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editi
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in A...
Precision BioSciences to Report First Quarter Results on May 13, 2024
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene
Precision BioSciences Gets FDA Fast Track Designation for Program to Treat Genetic Urea Cycle Disorder in Newborns
By Chris Wack Precision BioSciences said Tuesday that its partner, iECURE, has received Fast Track designation from the Food and Drug Administration for ECUR-506. ECUR-506 is iECURE's in vivo gene i
Why Precision BioSciences Is Rising In Pre-market?
IECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced
Precision Biosciences Disclosed Late-breaking Poster Presentation At The European Association For Study Of The Liver Congress 2024
Precision Biosciences Disclosed Late-breaking Poster Presentation At The European Association For Study Of The Liver Congress 2024
Precision Biosciences Initiated at Buy by Guggenheim
Precision Biosciences Initiated at Buy by Guggenheim
Analysis
Price Target
No Data
